<DOC>
	<DOC>NCT02240316</DOC>
	<brief_summary>This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.</brief_summary>
	<brief_title>An Observational Study of Patients With Malignant Lymphomas Treated With MabTheraÂ® SC in Everyday Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<criteria>Women and men aged &gt;=18 years Previously untreated CD20 positive follicular NHL Previously untreated CD20 positive DLBCL Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study) Suitability for the therapy with MabThera SC All contraindications, interactions and incompatibilities for therapy with MabThera SC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>